• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
PAN Yu,CHEN Weiwei,LIU Nan.Progress in the treatment of Bcl-2 inhibitor Venetoclax in B-cell lymphoma[J].Journal Of Pharmaceutical Research,2023,42(6):409-412[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2429times   Download 1864次 QR Code for this article
Scan with your phone!
Bcl-2抑制剂维奈克拉在B细胞淋巴瘤中的治疗进展
潘玉,陈伟伟,刘南
Font:Larger+|Default|Smaller-
(菏泽市立医院血液内科,山东 菏泽 274000)
摘要:
BCL-2是调节细胞凋亡的关键蛋白,在很多血液系统恶性肿瘤中高表达,发挥抗凋亡作用。维奈克拉是首个高度选择性的BCL-2抑制剂,在全球范围内其第一个适应证为慢性淋巴细胞白血病(CLL),目前临床研究更已拓展到多种B细胞淋巴瘤、骨髓增生异常综合征(MDS)等多个血液肿瘤。本文对维奈克拉在B细胞淋巴瘤中的治疗进展作一综述。
关键词:  维奈克拉  B细胞淋巴瘤  B细胞淋巴瘤因子-2  治疗  进展
DOI:10.13506/j.cnki.jpr.2023.06.011
基金项目:
Progress in the treatment of Bcl-2 inhibitor Venetoclax in B-cell lymphoma
PAN Yu,CHEN Weiwei,LIU Nan
(Department of Hematology, Heze Municipal Hospital in Shandong Province, Heze 274000, China)
Abstract:
Bcl-2 protein is a key protein in regulating cell apoptosis, which is highly expressed in many hematological malignancies and plays an anti-apoptotic role. Venetoclax is the first highly selective bcl-2 inhibitor. Its first indication in the world is chronic lymphocytic leukemia (CLL), and clinical studies have been extended to a variety of B-cell lymphoma, myelodysplastic syndrome (MDS) and other hematological tumors. This review reviewed the therapeutic progress of venetoclax in B-cell lymphoma.
Key words:  Venetoclax  B-cell lymphoma  Treatment  Progress
Today's Visits:527    Total Visits:2383269
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.